Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations

Mohammad Ali Sahraian*, Abdorreza Naser Moghadasi, Amir Reza Azimi, Nasrin Asgari, Fahimeh Haji Akhoundi, Roya Abolfazli, Shekoofeh Alaie, Fereshteh Ashtari, Hormoz Ayromlou, Seyed Mohammad Baghbanian, Nahid Beladi Moghadam, Farzad Fatehi, Mohsen Foroughipour, Hamidreza Ghalyanchi Langroodi, Nastaran Majdinasab, Alireza Nickseresht, Abbas Nourian, Vahid Shaygannejad, Hamid Reza Torabi

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftReviewForskningpeer review


    Neuromyelitis Optica Spectrum Disorder (NMOSD) is a relapsing neuro inflammatory disease of the central nervous system that typically presents with optic neuritis or myelitis and may cause severe disability. The diagnostic criteria have been updated and several immunosuppressive agents have been demonstrated to prevent acute exacerbations. As the disease rarely develops in a progressive course, management of acute attacks and proper prevention of exacerbations may change the long term out-come and prevent future disability. Consensus recommendations and guidelines will help the physicians to improve their practice and unify the treatment approaches in different communities. In order to develop a national consensus and recommendations for the diagnosis and management of NMOSD in Iran, a group of neurologists with long term experience in management of NMOSD were gathered to develop this consensus based on available national and international data. The primary draft was prepared and discussed to suggest the most appropriate treatment for these patients. We propose strategies for early diagnosis and treatment for prevention of relapses and minimizing consequences of attacks as a primary therapeutic goal. Attacks are currently treated with intravenous corticosteroids and, in refractory cases, with plasma exchange. All participants agreed on preventive treatment with currently available immunosuppressive agents such as azothioprin, rituximab and mycofenolate mofetil based on previous positive data in NMOSD in order to reduce attack frequency. The current consensus reviews the previous data and provides the clinicians with practical recommendations and advices for the diagnosis and management of NMOSD based on scientific data and clinical experience.

    Sider (fra-til)144-151
    Antal sider8
    TidsskriftMultiple Sclerosis and Related Disorders
    StatusUdgivet - 1 nov. 2017


    Udforsk hvilke forskningsemner 'Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations' indeholder.